HOME >> MEDICINE >> NEWS
ReQuip cuts risk of dyskinesias by 15-fold in early Parkinson's disease

Vancouver, Canada - A landmark, multinational, 5-year study shows that the dopamine-agonist ReQuip® (ropinirole hydrochloride, SmithKline Beecham) is associated with a much lower incidence of dyskinesias than L-dopa, and has comparable efficacy to L-dopa in the management of early Parkinson's Disease. The results of this exciting study are released today for the first time at the XIII International Congress on Parkinson's Disease (ICPD), Vancouver, 24-28 July, 1999.

"This landmark study should affect the future management of Parkinson's Disease. The data demonstrate that ropinirole is a first-line option for the initial treatment of early Parkinson's Disease," commented lead author of the study, Professor Olivier Rascol, Professor of Pharmacology at the Centre Hospitalier Universitaire, Toulouse, France.

"This is important news for patients, as we can now hope for good control of their symptoms with less risk of dyskinesias," concluded Dr Donald Calne, Chairman of the ICPD, and Director of the Neurodegenerative Disorders Centre, University of British Columbia, Vancouver, Canada.

The 268 patients participating in this double-blind controlled study, conducted in Europe, Israel and Canada, were randomised to receive either ReQuip® or L-dopa -- the current standard therapy. Both treatment groups were allowed to receive supplementary L-dopa if required.

The study demonstrated that the probability (odds ratio) of developing dyskinesias was 3.8 times higher for patients receiving L-dopa (incidence 46%) than for patients receiving ReQuip®, either alone or with additional L-dopa (incidence 20%). In patients who completed the trial on ReQuip® alone, the benefit was found to be even greater, with the relative probability of dyskinesias 15.2 times higher in the L-dopa group (incidence 36%) than the ReQuip® group (incidence 5%).

Over the 5-year study period, both groups of patients experienced similar control of their symptoms. A
'"/>

Contact: Kate Davies (Vancouver)
alexa@meditech.co.uk
44-780-840-345
MediTech Media Ltd.
26-Jul-1999


Page: 1 2

Related medicine news :

1. Clozapine effective for controlling dyskinesias in people with severe Parkinsons
2. New marker for early diagnosis of kidney failure identified
3. English-speaking Hispanic youth more likely to have sex early
4. Inpatient smoking cessation counseling is associated with early differences in mortality
5. Study finds no reason for expectant mothers to shy away from early epidurals
6. No increase in C-sections when epidural analgesia given early in labor
7. Radiologists offer non-surgical treatment for early-stage liver cancer
8. Researchers confirm Vioxx nearly doubled cardiovascular risks in cancer prevention study
9. A new method for early detection of disease outbreaks
10. UCLA study: Nearly a third of drug ads in medical journals contain no references for medical claims
11. Morbidly obese pay nearly twice as much for health care

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: ReQuip cuts risk dyskinesias fold early Parkinson disease

(Date:6/30/2015)... Scotch Plains, NJ (PRWEB) , ... June 30, 2015 , ... ... past May. On May 13th, she hosted a CPR Course for members of ... place where members can get updated on the latest CPR recommendations for Healthcare Providers. ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... imaging. The company provides high quality record management services for patient records. Medical ... is normally required by physicians and clinics. , With the increase in ...
(Date:6/30/2015)... , ... June 30, 2015 , ... ... call and communications software, Notify™, for the senior care sector. As an innovator ... helping senior housing facilities to become more efficient and offer residents better care. ...
(Date:6/30/2015)... , ... June 30, 2015 , ... Harbor Village ... affordable addiction care in Florida on June 12th. Holly Vasquez-Cortella was recently ... - a website dedicated to reporting on trending addiction news and treatment innovations. ...
(Date:6/30/2015)... ... June 30, 2015 , ... Nuretix Research, creators ... Knockout Zone Miami (KO Zone), a state-of-the-art training facility owned by ... Diego de Vera. The partnership will provide KO Zone clients and athletes with ...
Breaking Medicine News(10 mins):Health News:NJ Top Dentists Presents, Dr. Susan Goldfarb of Advanced Periodontics & Implant Care! 2Health News:NJ Top Dentists Presents, Dr. Susan Goldfarb of Advanced Periodontics & Implant Care! 3Health News:Micro Com Systems Ltd Now Specializes in Medical Imaging 2Health News:Eldermark Leap-Frogs other Nurse Call and Communication Systems with Notify 2Health News:Eldermark Leap-Frogs other Nurse Call and Communication Systems with Notify 3Health News:Harbor Village Detox’s Clinical Director Is Quoted as an Addiction Expert by The Fix 2Health News:Harbor Village Detox’s Clinical Director Is Quoted as an Addiction Expert by The Fix 3Health News:Top Sports Nutrition Brand, Liporidex, Announces Partnership With Leading Boxing, CrossFit and MMA Gym, Knockout Zone of Miami 2Health News:Top Sports Nutrition Brand, Liporidex, Announces Partnership With Leading Boxing, CrossFit and MMA Gym, Knockout Zone of Miami 3
(Date:6/30/2015)... LONDON , June 30, 2015 ... Street issued a survey to Rosacea sufferers as part of ... what treatments Rosacea sufferers found effective for their Rosacea. The ... age, and comprised 47% men and 53% women. ... of survey participants did not consider or attempt to visit ...
(Date:6/30/2015)... June 30, 2015 First Choice Wellness Care ... Astanza Duality and is the only clinic in the ... tattoo removal treatments. The practice has recently expanded their ... brand to showcase their focus in the procedure. They ... results, faster ink clearance, and superior service. ...
(Date:6/30/2015)... June 30, 2015  Avanir Pharmaceuticals, Inc. today ... showing that treatment with NUEDEXTA ® was ... of pseudobulbar affect (PBA) in patients with traumatic ... distressing condition characterized by sudden and uncontrollable outbursts ... diseases or brain injury. PRISM II is a ...
Breaking Medicine Technology:84% of Rosacea Sufferers Say NHS Treatments Were "Ineffective" New Survey Reveals 284% of Rosacea Sufferers Say NHS Treatments Were "Ineffective" New Survey Reveals 3First Choice Wellness Care Becomes Tallahassee Leader In Tattoo Removal With Astanza Duality 2First Choice Wellness Care Becomes Tallahassee Leader In Tattoo Removal With Astanza Duality 3Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 2Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 3Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 4Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 5Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 6Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 7
Cached News: